CA2662083C - Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health - Google Patents
Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health Download PDFInfo
- Publication number
- CA2662083C CA2662083C CA2662083A CA2662083A CA2662083C CA 2662083 C CA2662083 C CA 2662083C CA 2662083 A CA2662083 A CA 2662083A CA 2662083 A CA2662083 A CA 2662083A CA 2662083 C CA2662083 C CA 2662083C
- Authority
- CA
- Canada
- Prior art keywords
- plasminogen
- periodontal
- tissue
- periodontal disease
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000028169 periodontal disease Diseases 0.000 title claims abstract description 89
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 64
- 230000003239 periodontal effect Effects 0.000 title claims abstract description 60
- 206010052428 Wound Diseases 0.000 title claims abstract description 58
- 230000035876 healing Effects 0.000 title claims abstract description 27
- 230000001737 promoting effect Effects 0.000 title claims description 16
- 230000036541 health Effects 0.000 title abstract description 36
- 239000003596 drug target Substances 0.000 title description 3
- 102000013566 Plasminogen Human genes 0.000 claims abstract description 208
- 108010051456 Plasminogen Proteins 0.000 claims abstract description 208
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 238000011282 treatment Methods 0.000 claims abstract description 48
- 208000006389 Peri-Implantitis Diseases 0.000 claims abstract description 15
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 238000011321 prophylaxis Methods 0.000 claims abstract description 12
- 210000001519 tissue Anatomy 0.000 claims description 102
- 208000015181 infectious disease Diseases 0.000 claims description 58
- 230000001580 bacterial effect Effects 0.000 claims description 40
- 230000002458 infectious effect Effects 0.000 claims description 34
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 25
- 230000001338 necrotic effect Effects 0.000 claims description 24
- 108010049112 miniplasminogen Proteins 0.000 claims description 19
- 201000001245 periodontitis Diseases 0.000 claims description 18
- 108010087750 lysyl-plasminogen Proteins 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 15
- 230000002797 proteolythic effect Effects 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 239000007943 implant Substances 0.000 claims description 14
- 208000035143 Bacterial infection Diseases 0.000 claims description 11
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 11
- 208000007565 gingivitis Diseases 0.000 claims description 10
- 230000002068 genetic effect Effects 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108010073385 Fibrin Proteins 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 6
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 6
- 229950003499 fibrin Drugs 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 230000029774 keratinocyte migration Effects 0.000 claims description 6
- 239000000865 liniment Substances 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000006072 paste Substances 0.000 claims description 6
- 230000007838 tissue remodeling Effects 0.000 claims description 6
- 206010017533 Fungal infection Diseases 0.000 claims description 5
- 208000031888 Mycoses Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 230000001976 improved effect Effects 0.000 claims description 5
- 210000004969 inflammatory cell Anatomy 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 4
- 238000002316 cosmetic surgery Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000000606 toothpaste Substances 0.000 claims description 4
- 229940034610 toothpaste Drugs 0.000 claims description 4
- 206010018296 Gingivitis ulcerative Diseases 0.000 claims description 3
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 3
- 201000010927 Mucositis Diseases 0.000 claims description 3
- 238000011200 topical administration Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 238000007910 systemic administration Methods 0.000 claims description 2
- 241000021559 Dicerandra Species 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000037361 pathway Effects 0.000 abstract description 37
- 241000699670 Mus sp. Species 0.000 description 129
- 108010088842 Fibrinolysin Proteins 0.000 description 69
- 229940012957 plasmin Drugs 0.000 description 69
- 230000002950 deficient Effects 0.000 description 59
- 238000000034 method Methods 0.000 description 52
- 210000000988 bone and bone Anatomy 0.000 description 37
- 241000894006 Bacteria Species 0.000 description 35
- 238000002347 injection Methods 0.000 description 34
- 239000007924 injection Substances 0.000 description 34
- 239000013543 active substance Substances 0.000 description 26
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 25
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 23
- 230000007123 defense Effects 0.000 description 23
- 206010028851 Necrosis Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 230000017074 necrotic cell death Effects 0.000 description 22
- 210000000629 knee joint Anatomy 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 16
- 102000001938 Plasminogen Activators Human genes 0.000 description 15
- 108010001014 Plasminogen Activators Proteins 0.000 description 15
- 210000001847 jaw Anatomy 0.000 description 15
- 229940127126 plasminogen activator Drugs 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 238000011081 inoculation Methods 0.000 description 14
- 230000000877 morphologic effect Effects 0.000 description 14
- 230000033885 plasminogen activation Effects 0.000 description 14
- 208000004575 Infectious Arthritis Diseases 0.000 description 12
- 208000025255 bacterial arthritis Diseases 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 108010015052 miniplasmin Proteins 0.000 description 12
- 210000004872 soft tissue Anatomy 0.000 description 12
- 230000002269 spontaneous effect Effects 0.000 description 11
- 230000009885 systemic effect Effects 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 9
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 9
- 108010023197 Streptokinase Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 229960005202 streptokinase Drugs 0.000 description 9
- 230000009469 supplementation Effects 0.000 description 9
- 101710145796 Staphylokinase Proteins 0.000 description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 108010058207 Anistreplase Proteins 0.000 description 7
- 229930040373 Paraformaldehyde Natural products 0.000 description 7
- 108010039185 Tenecteplase Proteins 0.000 description 7
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 7
- 229960003318 alteplase Drugs 0.000 description 7
- 229960000983 anistreplase Drugs 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 108010051044 lanoteplase Proteins 0.000 description 7
- 229950010645 lanoteplase Drugs 0.000 description 7
- 108010075698 monteplase Proteins 0.000 description 7
- 229950005805 monteplase Drugs 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 108010085108 pamiteplase Proteins 0.000 description 7
- 229950003603 pamiteplase Drugs 0.000 description 7
- 229920002866 paraformaldehyde Polymers 0.000 description 7
- 108010051412 reteplase Proteins 0.000 description 7
- 229960002917 reteplase Drugs 0.000 description 7
- 210000003296 saliva Anatomy 0.000 description 7
- 108010073863 saruplase Proteins 0.000 description 7
- 229960002055 saruplase Drugs 0.000 description 7
- -1 tPA Proteins 0.000 description 7
- 229960000216 tenecteplase Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000006142 Luria-Bertani Agar Substances 0.000 description 5
- 244000062730 Melissa officinalis Species 0.000 description 5
- 208000002847 Surgical Wound Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000004053 dental implant Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 4
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 210000000845 cartilage Anatomy 0.000 description 4
- 210000003855 cell nucleus Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000004195 gingiva Anatomy 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 241000589969 Borreliella burgdorferi Species 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 241000605862 Porphyromonas gingivalis Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 229940051866 mouthwash Drugs 0.000 description 3
- 210000004261 periodontium Anatomy 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000589996 Campylobacter rectus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000008952 bacterial invasion Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000024693 gingival disease Diseases 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000002050 maxilla Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 210000002379 periodontal ligament Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 206010063746 Accidental death Diseases 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- 102100038910 Alpha-enolase Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 229920001605 Dextranomer Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000002354 Edentulous Jaw Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 208000034619 Gingival inflammation Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 101000610236 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) Protein PatA Proteins 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100037882 Perilipin-5 Human genes 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 102100039419 Plasminogen activator inhibitor 2 Human genes 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 206010036595 Premature delivery Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 1
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 1
- 102000019400 Tissue-type plasminogen activator Human genes 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- KRPUGSACBHJZSR-UHFFFAOYSA-N [3-oxo-2-phenyl-3-(pyridin-2-ylmethylamino)propyl] acetate Chemical compound C=1C=CC=CC=1C(COC(=O)C)C(=O)NCC1=CC=CC=N1 KRPUGSACBHJZSR-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000033608 aggressive 1 periodontitis Diseases 0.000 description 1
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000034391 chronic adult periodontitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000002169 hydrotherapy Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010883 osseointegration Methods 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 101150101567 pat-2 gene Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000003784 poor nutrition Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010029690 procollagenase Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 229940115037 santyl Drugs 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82366506P | 2006-08-28 | 2006-08-28 | |
| US60/823,665 | 2006-08-28 | ||
| US94411107P | 2007-06-15 | 2007-06-15 | |
| US60/944,111 | 2007-06-15 | ||
| PCT/SE2007/050586 WO2008027000A2 (en) | 2006-08-28 | 2007-08-28 | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2662083A1 CA2662083A1 (en) | 2008-03-06 |
| CA2662083C true CA2662083C (en) | 2016-09-20 |
Family
ID=39136398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2662083A Expired - Fee Related CA2662083C (en) | 2006-08-28 | 2007-08-28 | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20100028321A1 (https=) |
| EP (1) | EP2056865B1 (https=) |
| JP (1) | JP5566106B2 (https=) |
| AU (1) | AU2007290882B2 (https=) |
| CA (1) | CA2662083C (https=) |
| DK (1) | DK2056865T3 (https=) |
| ES (1) | ES2453496T3 (https=) |
| WO (1) | WO2008027000A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2849268C1 (ru) * | 2025-04-21 | 2025-10-23 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Способ лечения периимплантита |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007290881B2 (en) | 2006-08-28 | 2013-03-07 | Omnio Healer Ab | Candidates against infection |
| US20130164228A1 (en) * | 2011-12-21 | 2013-06-27 | Colgate-Palmolive Company | Compositions comprising gallates and gallamides |
| US9723558B2 (en) | 2012-04-27 | 2017-08-01 | Qualcomm Incorporated | Method and apparatus for signaling in dense network operations |
| CN104721621A (zh) * | 2015-03-24 | 2015-06-24 | 孟勇 | 一种治疗种植体周围炎的药物组合物及其应用 |
| ES2671844B1 (es) | 2015-06-11 | 2019-03-22 | Attwill Medical Solutions Inc | Dispositivos médicos, sistemas y métodos que utilizan composiciones de anti-trombina heparina. |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| HK1259294A1 (zh) * | 2015-11-10 | 2019-11-29 | 耶鲁大学 | 用於治疗自身免疫疾病和癌症的组合物及方法 |
| JP6876066B2 (ja) * | 2015-12-18 | 2021-05-26 | タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 子宮膣部びらんを予防及び治療するための方法 |
| TWI624268B (zh) | 2015-12-18 | 2018-05-21 | Talengen Institute Of Life Sciences Co Ltd | 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑 |
| WO2018107688A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗脂肪肝的方法 |
| TWI746581B (zh) * | 2016-12-15 | 2021-11-21 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途 |
| WO2018107707A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种改善心脏病变的方法 |
| US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| TWI787732B (zh) * | 2020-02-06 | 2022-12-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種預防和治療多發性硬化症的方法和藥物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3023143A (en) | 1959-10-14 | 1962-02-27 | American Cyanamid Co | Process for preparing a veterinary composition |
| AT402367B (de) * | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
| US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US5792835A (en) * | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
| US5397578A (en) | 1994-03-29 | 1995-03-14 | Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" | Method of treatment of chronic purulent inflammations of ear in children |
| US6420622B1 (en) | 1997-08-01 | 2002-07-16 | 3M Innovative Properties Company | Medical article having fluid control film |
| AU5390699A (en) * | 1998-07-24 | 2000-02-14 | Pharmacal Biotechnologies, Inc. | Osseous tissue reconstruction system and method |
| AU3862900A (en) * | 1999-03-01 | 2000-09-21 | Uab Research Foundation | Porous tissue scaffolding materials and uses thereof |
| US20030026794A1 (en) * | 2001-07-31 | 2003-02-06 | Howard Fein | Selective enzyme treatment of skin conditions |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| JP4458240B2 (ja) * | 2001-11-26 | 2010-04-28 | ジェネンテック インコーポレイテッド | カテーテル組成物とその用途 |
| AU2003210137A1 (en) | 2002-02-06 | 2003-09-02 | N-Zyme Biotec Gmbh | Method for producing recombinant proteins in micro-organisms |
| CN1420126A (zh) | 2002-07-10 | 2003-05-28 | 牛勃 | 一种重组人纤溶酶原Kringle5突变体蛋白rhPK－5的制备方法 |
| AU2007290881B2 (en) | 2006-08-28 | 2013-03-07 | Omnio Healer Ab | Candidates against infection |
-
2007
- 2007-08-28 US US12/439,516 patent/US20100028321A1/en not_active Abandoned
- 2007-08-28 DK DK07794196.1T patent/DK2056865T3/en active
- 2007-08-28 EP EP07794196.1A patent/EP2056865B1/en not_active Not-in-force
- 2007-08-28 AU AU2007290882A patent/AU2007290882B2/en not_active Ceased
- 2007-08-28 CA CA2662083A patent/CA2662083C/en not_active Expired - Fee Related
- 2007-08-28 ES ES07794196.1T patent/ES2453496T3/es active Active
- 2007-08-28 JP JP2009526573A patent/JP5566106B2/ja not_active Expired - Fee Related
- 2007-08-28 WO PCT/SE2007/050586 patent/WO2008027000A2/en not_active Ceased
-
2015
- 2015-10-23 US US14/921,758 patent/US10086052B2/en active Active
-
2018
- 2018-08-28 US US16/114,940 patent/US20180360931A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2849268C1 (ru) * | 2025-04-21 | 2025-10-23 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Способ лечения периимплантита |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5566106B2 (ja) | 2014-08-06 |
| WO2008027000A3 (en) | 2008-05-22 |
| US20100028321A1 (en) | 2010-02-04 |
| JP2010502601A (ja) | 2010-01-28 |
| AU2007290882B2 (en) | 2013-02-21 |
| EP2056865B1 (en) | 2013-12-25 |
| US20180360931A1 (en) | 2018-12-20 |
| EP2056865A2 (en) | 2009-05-13 |
| EP2056865A4 (en) | 2012-01-25 |
| AU2007290882A1 (en) | 2008-03-06 |
| ES2453496T3 (es) | 2014-04-08 |
| US10086052B2 (en) | 2018-10-02 |
| US20160184411A1 (en) | 2016-06-30 |
| DK2056865T3 (en) | 2014-03-24 |
| CA2662083A1 (en) | 2008-03-06 |
| WO2008027000A2 (en) | 2008-03-06 |
| HK1134788A1 (en) | 2010-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2662083C (en) | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health | |
| CN101563100B (zh) | 用于预防和治疗牙周病、改善牙周创伤愈合以及促进口腔健康的新药物靶标 | |
| RU2241489C2 (ru) | Композиции матриксных протеинов для залечивания ран | |
| JP5024866B2 (ja) | 創傷治癒のためのマトリックスタンパク質組成物 | |
| Aboyoussef et al. | Detection of Prostaglandin E 2 and Matrix Metalloproteinases in Implant Crevicular Fluid. | |
| JP2007291115A6 (ja) | 創傷治癒のためのマトリックスタンパク質組成物 | |
| EP3413881B1 (en) | Compositions and methods for treating chronic wounds | |
| Ingman et al. | Collagenase, gelatinase and elastase activities in sulcular fluid of osseointegrated implants and natural teeth | |
| HK1134788B (en) | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health | |
| Pietruska et al. | Assessment of aprotinin influence on periodontal clinical status and matrix metalloproteinases 1, 2 and their tissue inhibitors saliva concentrations in patients with chronic periodontitis | |
| Zarandi et al. | Efect of Anaheal (Bromelain) drug on the Periodontal Clinical Indices in Nonsurgical Periodontal treatment of patients with chronic Periodontitis | |
| Deppe et al. | Content of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in oral mucosa and inflamed periodontal tissue. | |
| Kondo et al. | Increased expression of angiopoietin‐like protein 4 regulates matrix metalloproteinase‐13 expression in Porphyromonas gingivalis lipopolysaccharides‐stimulated gingival fibroblasts and ligature‐induced experimental periodontitis | |
| Kałużna-Różańska et al. | Urokinase-Plasminogen Activator in Periodontitis: Role, Mechanisms and Therapeutic Potential | |
| Wahlgren | Matrix metalloproteinases in pulpitis, chronic apical periodontitis and odontogenic jaw cysts | |
| Boushell | Distribution of matrixmetalloproteinase-2 in human coronal dentin | |
| Aslam | Double blind study on the efficacy of local application of haemocoagulase solution in wound healing | |
| Korpi | Collagenase-2 (matrix metalloproteinase-8) in tongue squamous cell carcinoma, bone osteosarcoma, and wound repair | |
| Pham | Epsilon aminocaproic acid: its effect on the healing of dental extraction sites. | |
| D OSA–TOM | Nina-Li Avellán Academic Dissertation | |
| Prajapati | The regulation of proteases and mechanical loading during fibroblast populated collagen lattice contraction | |
| Delima | Pre-Wounding and Free Gingival Grafts: A Pilot Investigation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20210830 |